Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 0.55 |
| ▸ | PRKDC | P78527 | 6/20 | 0.55 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3461032 | 0.86 | ATR (0.65) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL3462566 | 0.82 | ATR (0.66) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL3459711 | 0.82 | ATR (0.56) | ATRPRKDC | |
| SCHEMBL3409514 | 0.82 | ATR (0.52) | ATR | |
| SCHEMBL557297 | 0.81 | ATR (0.60) | ATRPRKDCATM | |
| SCHEMBL14525246 | 0.79 | ATR (0.65) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL318797 | 0.78 | ATR (0.68) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL3406909 | 0.77 | ATR (0.44) | ATRPRKDC | |
| SCHEMBL12343675 | 0.77 | GRM5 (0.45) | ATR | |
| SCHEMBL24248259 | 0.77 | ATR (0.67) | ATRPRKDCATMCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771362-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-26 | — | — | US | disclosed |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-03-09 | — | — | US | disclosed |
| US-9394301-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-09-03 | — | — | US | disclosed |
| US-9012633-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| EP-2217578-B9 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-09-10 | — | — | EP | disclosed |
| US-20140155594-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-06-05 | — | — | US | disclosed |
| EP-2217578-B1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2013-12-04 | — | — | EP | disclosed |
| US-8431596-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2217578-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-08-18 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| WO-2009047514-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | ATR 127/4885PRKDC 338/4885ATM 454/4885 |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | ATR 127/4885PRKDC 338/4885ATM 454/4885 |
| US-20140155594-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | ATR 127/4885PRKDC 338/4885ATM 454/4885 |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | ATR 127/4885PRKDC 338/4885ATM 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.